CD20 positive CD8 T cells are a unique and transcriptionally-distinct subset of T cells with distinct transmigration properties.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
15 10 2021
Historique:
received: 03 03 2021
accepted: 05 10 2021
entrez: 16 10 2021
pubmed: 17 10 2021
medline: 28 1 2022
Statut: epublish

Résumé

The presence of T cells that are dimly positive for the B cell marker CD20 is well-established in autoimmunity and correlates with disease severity in various diseases. Further, we previously identified that the level of CD20-positive T cells was three-fourfold elevated in ascites fluid of ovarian carcinoma patients, together suggesting a role in both autoimmunity and cancer. In this respect, treatment of autoimmune patients with the CD20-targeting antibody Rituximab has also been shown to target and deplete CD20-positive T cells, previously identified as IFN-gamma producing, low proliferative, CD8 cytotoxic T cells with an effector memory (EM) differentiation state. However, the exact phenotype and relevance of CD20-positive T cells remains unclear. Here, we set out to identify the transcriptomic profile of CD20-positive T cells using RNA sequencing. Further, to gain insight into potential functional properties of CD20 expression in T cells, CD20 was ectopically expressed on healthy human T cells and phenotypic, functional, migratory and adhesive properties were determined in vitro and in vivo. Together, these assays revealed a reduced transmigration and an enhanced adhesive profile combined with an enhanced activation status for CD20-positive T cells.

Identifiants

pubmed: 34654826
doi: 10.1038/s41598-021-00007-0
pii: 10.1038/s41598-021-00007-0
pmc: PMC8520003
doi:

Substances chimiques

Antigens, CD20 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

20499

Subventions

Organisme : Marie Curie
ID : No 813871
Pays : United Kingdom

Informations de copyright

© 2021. The Author(s).

Références

Browning, J. L. B cells move to centre stage: Novel opportunities for autoimmune disease treatment. Nat. Rev. Drug Discov. 5(7), 564–576 (2006).
pubmed: 16816838 doi: 10.1038/nrd2085
Marcus, R. & Hagenbeek, A. The therapeutic use of rituximab in non-Hodgkin’s lymphoma. Eur. J. Haematol. Suppl. 67, 5–14 (2007).
doi: 10.1111/j.1600-0609.2006.00789.x
Wilk, E. et al. Depletion of functionally active CD20+ T cells by rituximab treatment. Arthritis Rheum. 60(12), 3563–3571 (2009).
pubmed: 19950291 doi: 10.1002/art.24998
Gingele, S. et al. Ocrelizumab depletes CD20(+) T cells in multiple sclerosis patients. Cells 8, 1 (2018).
doi: 10.3390/cells8010012
Schuh, E. et al. Features of human CD3+CD20+ T cells. J. Immunol. 197(4), 1111–1117 (2016).
pubmed: 27412413 doi: 10.4049/jimmunol.1600089
Chen, Q. et al. CD3(+)CD20(+) T cells and their roles in human diseases. Hum. Immunol. 80(3), 191–194 (2019).
pubmed: 30639700 doi: 10.1016/j.humimm.2019.01.001
Niu, J. et al. Dissection of a circulating CD3(+) CD20(+) T cell subpopulation in patients with psoriasis. Clin. Exp. Immunol. 192(2), 206–212 (2018).
pubmed: 29377068 pmcid: 5904720 doi: 10.1111/cei.13106
Eggleton, P. et al. Frequency of Th17 CD20+ cells in the peripheral blood of rheumatoid arthritis patients is higher compared to healthy subjects. Arthritis Res. Ther. 13(6), R208 (2011).
pubmed: 22171710 pmcid: 3334661 doi: 10.1186/ar3541
Holley, J. E. et al. CD20+inflammatory T-cells are present in blood and brain of multiple sclerosis patients and can be selectively targeted for apoptotic elimination. Mult. Scler. Relat. Disord. 3(5), 650–658 (2014).
pubmed: 26265276 doi: 10.1016/j.msard.2014.06.001
von Essen, M. R. et al. Proinflammatory CD20+ T cells in the pathogenesis of multiple sclerosis. Brain 142(1), 120–132 (2019).
doi: 10.1093/brain/awy301
Carden, M. A. et al. Rituximab leads to early elimination of circulating CD20+ T and B lymphocytes in patients with iTTP despite ongoing TPEx. Blood Adv. 4(3), 477–481 (2020).
pubmed: 32027742 pmcid: 7013265 doi: 10.1182/bloodadvances.2019001148
Serra-Peinado, C. et al. Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab. Nat. Commun. 10(1), 3705 (2019).
pubmed: 31420544 pmcid: 6697690 doi: 10.1038/s41467-019-11556-4
de Bruyn, M. et al. CD20(+) T cells have a predominantly Tc1 effector memory phenotype and are expanded in the ascites of patients with ovarian cancer. Oncoimmunology 4(4), e999536 (2015).
pubmed: 26137418 pmcid: 4485721 doi: 10.1080/2162402X.2014.999536
Storie, I. et al. Circulating CD20dim T-lymphocytes increase with age: Evidence for a memory cytotoxic phenotype. Cli. Lab. Haematol. 17(4), 323–328 (1995).
Human Tissue and Medical Research: Code of Conduct for responsible use. 2011; Available from: https://www.federa.org/sites/default/files/images/print_version_code_of_conduct_english.pdf .
Yang, M. et al. CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer. J. Immunother. Cancer 9, 1 (2021).
doi: 10.1136/jitc-2020-001136
Workel, H. H. et al. A Transcriptionally distinct CXCL13(+)CD103(+)CD8(+) T-cell population is associated with B-cell recruitment and neoantigen load in human cancer. Cancer Immunol. Res. 7(5), 784–796 (2019).
pubmed: 30872264 doi: 10.1158/2326-6066.CIR-18-0517
Chen, E. Y. et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinform. 14, 128 (2013).
doi: 10.1186/1471-2105-14-128
Kuleshov, M. V. et al. Enrichr: A comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 44(W1), W90–W97 (2016).
pubmed: 27141961 pmcid: 4987924 doi: 10.1093/nar/gkw377
Xie, Z. et al. Gene set knowledge discovery with enrichr. Curr. Protoc. 1(3), e90 (2021).
pubmed: 33780170 doi: 10.1002/cpz1.90 pmcid: 8152575
Dennis, G. Jr. et al. DAVID: Database for annotation, visualization, and integrated discovery. Genome Biol. 4(5), P3 (2003).
pubmed: 12734009 doi: 10.1186/gb-2003-4-5-p3
da Huang, W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4(1), 44–57 (2009).
doi: 10.1038/nprot.2008.211
van Meerten, T. et al. Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. Clin. Cancer Res. 12(13), 4027–4035 (2006).
pubmed: 16818702 doi: 10.1158/1078-0432.CCR-06-0066
van Meerten, T. & Hagenbeek, A. CD20-targeted therapy: The next generation of antibodies. Semin. Hematol. 47(2), 199–210 (2010).
pubmed: 20350667 doi: 10.1053/j.seminhematol.2010.01.007
Tiemessen, M. M. et al. Cow’s milk-specific T-cell reactivity of children with and without persistent cow’s milk allergy: Key role for IL-10. J. Allergy Clin. Immunol. 113(5), 932–939 (2004).
pubmed: 15131577 doi: 10.1016/j.jaci.2003.12.016
van Rijn, R. S. et al. A new xenograft model for graft-versus-host disease by intravenous transfer of human peripheral blood mononuclear cells in RAG2-/- gammac-/- double-mutant mice. Blood 102(7), 2522–2531 (2003).
pubmed: 12791667 doi: 10.1182/blood-2002-10-3241
van Rijn, R. S. et al. Quantitative assessment of human T lymphocytes in RAG2(-/-)gammac(-/-) mice: The impact of ex vivo manipulation on in vivo functionality. Exp. Hematol. 35(1), 117–127 (2007).
pubmed: 17198880 doi: 10.1016/j.exphem.2006.09.018
Pilling, et al. Expression of α
pubmed: 9790314 doi: 10.1046/j.1365-3083.1998.00424.x
Ooshio, T. et al. Involvement of LMO7 in the association of two cell-cell adhesion molecules, nectin and E-cadherin, through afadin and alpha-actinin in epithelial cells. J. Biol. Chem. 279(30), 31365–31373 (2004).
pubmed: 15140894 doi: 10.1074/jbc.M401957200
Unsoeld, H. & Pircher, H. Complex memory T-cell phenotypes revealed by coexpression of CD62L and CCR7. J. Virol. 79(7), 4510–4513 (2005).
pubmed: 15767451 pmcid: 1061544 doi: 10.1128/JVI.79.7.4510-4513.2005
Ivetic, A., Hoskins Green, H. L. & Hart, S. J. L-selectin: A major regulator of leukocyte adhesion migration and signaling. Front. Immunol. 10, 1068 (2019).
pubmed: 31139190 pmcid: 6527602 doi: 10.3389/fimmu.2019.01068
Watson, H. A. et al. L-selectin enhanced T cells improve the efficacy of cancer immunotherapy. Front. Immunol. 10, 1321 (2019).
pubmed: 31249570 pmcid: 6582763 doi: 10.3389/fimmu.2019.01321
Berg, E. L. et al. The human peripheral lymph node vascular addressin is a ligand for LECAM-1, the peripheral lymph node homing receptor. J. Cell Biol. 114(2), 343–349 (1991).
pubmed: 1712790 doi: 10.1083/jcb.114.2.343
Arbones, M. L. et al. Lymphocyte homing and leukocyte rolling and migration are impaired in L-selectin-deficient mice. Immunity 1(4), 247–260 (1994).
pubmed: 7534203 doi: 10.1016/1074-7613(94)90076-0
Dauner, J. G., Williams, I. R. & Jacob, J. Differential microenvironment localization of effector and memory CD8 T cells. J. Immunol. 180(1), 291–299 (2008).
pubmed: 18097030 doi: 10.4049/jimmunol.180.1.291
Jung, Y. W. et al. Differential localization of effector and memory CD8 T cell subsets in lymphoid organs during acute viral infection. J. Immunol. 185(9), 5315–5325 (2010).
pubmed: 20921525 doi: 10.4049/jimmunol.1001948
Liu, W. et al. Mechanism for KRIT1 release of ICAP1-mediated suppression of integrin activation. Mol. Cell 49(4), 719–729 (2013).
pubmed: 23317506 pmcid: 3684052 doi: 10.1016/j.molcel.2012.12.005
Fournier, H. N. et al. Nuclear translocation of integrin cytoplasmic domain-associated protein 1 stimulates cellular proliferation. Mol. Biol. Cell 16(4), 1859–1871 (2005).
pubmed: 15703214 pmcid: 1073667 doi: 10.1091/mbc.e04-08-0744
Jung, J. et al. Calnexin is necessary for T cell transmigration into the central nervous system. JCI Insight 3, 5 (2018).
doi: 10.1172/jci.insight.98410
Chen, Y. et al. Calnexin impairs the antitumor immunity of CD4(+) and CD8(+) T cells. Cancer Immunol. Res. 7(1), 123–135 (2019).
pubmed: 30401678 doi: 10.1158/2326-6066.CIR-18-0124
Chrifi, I. et al. CMTM3 (CKLF-like marvel transmembrane domain 3) mediates angiogenesis by regulating cell surface availability of VE-cadherin in endothelial adherens junctions. Arterioscler. Thromb. Vasc. Biol. 37(6), 1098–1114 (2017).
pubmed: 28428220 doi: 10.1161/ATVBAHA.116.308792
Zhao, X. et al. SRF expedites metastasis and modulates the epithelial to mesenchymal transition by regulating miR-199a-5p expression in human gastric cancer. Cell Death Differ. 21(12), 1900–1913 (2014).
pubmed: 25080937 pmcid: 4227147 doi: 10.1038/cdd.2014.109
Miyazaki, T. et al. EBAG9 modulates host immune defense against tumor formation and metastasis by regulating cytotoxic activity of T lymphocytes. Oncogenesis 3, e126 (2014).
pubmed: 25365482 pmcid: 4259964 doi: 10.1038/oncsis.2014.40
Adams, R. A. et al. Serum-circulating His-tRNA synthetase inhibits organ-targeted immune responses. Cell Mol. Immunol. 2, 2 (2019).
Mertsching, E. C. et al. Identification of a T cell immunomodulatory domain in histidyl-tRNA synthetase. J. Immunol. 200(1), 112 (2018).
Rangachari, M. et al. Bat3 promotes T cell responses and autoimmunity by repressing Tim-3-mediated cell death and exhaustion. Nat. Med. 18(9), 1394–1400 (2012).
pubmed: 22863785 pmcid: 3491118 doi: 10.1038/nm.2871
Karasawa, T. et al. Oligomerized CARD16 promotes caspase-1 assembly and IL-1beta processing. FEBS Open Bio 5, 348–356 (2015).
pubmed: 25973362 pmcid: 4420773 doi: 10.1016/j.fob.2015.04.011
Siegfried, A. et al. IFIT2 is an effector protein of type I IFN-mediated amplification of lipopolysaccharide (LPS)-induced TNF-alpha secretion and LPS-induced endotoxin shock. J. Immunol. 191(7), 3913–3921 (2013).
pubmed: 24014876 doi: 10.4049/jimmunol.1203305
Welsby, I. et al. PARP12, an interferon-stimulated gene involved in the control of protein translation and inflammation. J. Biol. Chem. 289(38), 26642–26657 (2014).
pubmed: 25086041 pmcid: 4176246 doi: 10.1074/jbc.M114.589515
Chai, R. C. et al. Systematically profiling the expression of eIF3 subunits in glioma reveals the expression of eIF3i has prognostic value in IDH-mutant lower grade glioma. Cancer Cell Int. 19, 155 (2019).
pubmed: 31171919 pmcid: 6549376 doi: 10.1186/s12935-019-0867-1
Diener, C. et al. Modulation of intracellular calcium signaling by microRNA-34a-5p. Cell Death Dis. 9(10), 1008 (2018).
pubmed: 30262862 pmcid: 6160487 doi: 10.1038/s41419-018-1050-7
Kidani, Y. et al. Sterol regulatory element-binding proteins are essential for the metabolic programming of effector T cells and adaptive immunity. Nat. Immunol. 14(5), 489–499 (2013).
pubmed: 23563690 pmcid: 3652626 doi: 10.1038/ni.2570
Bancos, S. et al. Dysfunctional memory CD8+ T cells after priming in the absence of the cell cycle regulator E2F4. Cell Immunol. 257(1–2), 44–54 (2009).
pubmed: 19306992 pmcid: 2727064 doi: 10.1016/j.cellimm.2009.02.006
Hu, Y. et al. Smad4 promotes differentiation of effector and circulating memory CD8 T cells but is dispensable for tissue-resident memory CD8 T cells. J. Immunol. 194(5), 2407–2414 (2015).
pubmed: 25637015 pmcid: 4337487 doi: 10.4049/jimmunol.1402369
Weng, N. P., Araki, Y. & Subedi, K. The molecular basis of the memory T cell response: Differential gene expression and its epigenetic regulation. Nat. Rev. Immunol. 12(4), 306–315 (2012).
pubmed: 22421787 pmcid: 4686144 doi: 10.1038/nri3173
Kozlova, V. et al. CD20 is dispensable for B-cell receptor signaling but is required for proper actin polymerization, adhesion and migration of malignant B cells. PLoS ONE 15(3), e0229170 (2020).
pubmed: 32210425 pmcid: 7094844 doi: 10.1371/journal.pone.0229170
Muller, G., Hopken, U. E. & Lipp, M. The impact of CCR7 and CXCR5 on lymphoid organ development and systemic immunity. Immunol. Rev. 195, 117–135 (2003).
pubmed: 12969315 doi: 10.1034/j.1600-065X.2003.00073.x

Auteurs

Martijn Vlaming (M)

Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. M.R.Vlaming@umcg.nl.

Vrouyr Bilemjian (V)

Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Jimena Álvarez Freile (JÁ)

Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Harm Jan Lourens (HJ)

Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Nienke van Rooij (N)

Department of Obstetrics and Gynecology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Gerwin Huls (G)

Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Tom van Meerten (T)

Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Marco de Bruyn (M)

Department of Obstetrics and Gynecology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Edwin Bremer (E)

Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. E.Bremer@umcg.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH